228 results about "Compounding drugs" patented technology

The invention relates to a novel liver target drug carrier-glycyrrhetinic acid-polyethylene glycol/chitosan or chitosan derivative liver target compound drug delivery system. During the preparation of the nano-drug delivery system, the liver target small-molecule glycyrrhetinic acid is firstly used for modifying amino polyethylene glycol by the different sites, then a water soluble big-molecule liver target compound is prepared and is mixed with a solution containing chitosan or chitosan derivative by a certain proportion, an ion cross-linking agent is added under the stirring condition, and a target group is introduced at the same time of the spontaneous formation of nanoparticles by physical winding and electrostatic interaction. The method of introducing the target group of the invention is novel, the formation of spheres is simple, the conditions are moderate, and the content of the target group is high (the weight percentage of glycyrrhetinic acid is 5 to 30 percent). The drug delivery system has strong killing capacity to the cancer cells, the in vitro experiments show that the drug delivery system has very strong binding capacity with the liver cells, and the high content of the target group can improve the liver target capacity of the drug delivery system, realize the target positioning of the liver and open a new way for the treatment of liver cancer.

The invention discloses a long acting slow-release drug carrier material for therapy and repair of bone disease and preparation method; wherein, the components of the drug carrier material are 4-8 weight account of strontium-doped calcium polyphosphate, 1-3 weight account of chitosan drug-loaded microspheres and 1-3 weight account of chitosan; the preparation method of the compound drug carrier material for therapy of osteomyelitis and other bone diseases is that (1) the chitosan-acetic acid solution is prepared, (2) the strontium-doped calcium polyphosphate powder is put into the chitosan-acetic acid solution and dispersed evenly, (3) the prepared chitosan drug-loaded microspheres is added, (4) the cross-linking agent is added for cross-linking, (5) freezing at temperature of 2-6 DEG C is processed for 12-48 hours, and (6) heating and drying are processed at temperature of 40-100 DEG C. The drug carrier material has the advantages of being applicable to therapy and repair of osteomyelitis and other bone diseases, releasing antibiotic for a long period, bone repair function, good biocompatibility and degradability, and ideal double function of therapy and repair of osteomyelitis and other bone diseases.

The invention provides application of fluorescence arborization nanometer macromolecule in preparing a drug carrier, application of the fluorescence arborization nanometer macromolecule in preparing a compound drug and the compound drug made of the drug carrier and a hydrophobic drug in a mixing mode, and further provides application of the compound drug in pest control. Pests are fed with the compound drug in a feeding or injecting mode, the arborization compound can serve as the drug carrier to package the drug to enter the cells of the pests quickly, the drug can play a role in the pests, the pesticide effect is enhanced, and non-target pests are effectively killed. The new strategy that the fluorescence arborization nanometer macromolecule serves as the pesticide carrier to be applied in the field of pest control is achieved successfully. The pesticide effect of the pesticide is enhanced through the application, the pest killing range is enlarged, and a new approach for avoiding overusing of chemical pesticide is provided. The fluorescence arborization nanometer macromolecule has very high application value in the fields of agricultural pest control and biology scientific research.

The invention discloses a preparation method of injectable chitosan grafted cyclodextrin compound drug-carrying hydrogel. The preparation method comprises the steps of carrying out amination and hydroformylation on cyclodextrin, reacting by virtue of hydroformylated cyclodextrin with chitosan so as to obtain chitosan grafted cyclodextrin, soaking molecules of obtained chitosan grafted cyclodextrin into medical liquid, uniformly stirring, filtering, carrying out freeze drying so as to obtain drug-carrying chitosan grafted cyclodextrin, adding drug-carrying chitosan grafted cyclodextrin into a chitosan water solution, adding beta-sodium glycerophosphate, so as to obtain the injectable chitosan grafted cyclodextrin compound drug-carrying hydrogel. The preparation method has the beneficial effects that reaction conditions are mild, and the operation is relatively simple and convenient; the stability of a drug concentration in a gel system of the prepared hydrogel can be maintained for a long time, and a drug can be effectively and controllably released for a long time, so that the utilization rate of the drug is increased; and the preparation method has relatively wide application prospects.

The invention provides a piezoelectric composite dressing for promoting peripheral nerve repair and wound healing and loading exosome of traditional Chinese medicine and a preparation method. The preparation method comprises the following steps that gelatin and methacrylic anhydride react to prepare methacrylate gelatin; the exosome of the Chinese medicine is prepared through differential centrifugation;a conductive pregel system is prepared through the recombination of gold nanorods, the exosome and the methacrylate gelatin; and the conductive pregel and a polyvinylidene fluoride ethylene piezoelectric thin film arerecombined, and the piezoelectric composite dressing is prepared. The dressing prepared by the preparation method is a novel dressing for piezoelectric stimulation composite medicine action, polyvinylidene fluoride ethylene produces electricity potential to stimulate a wound area through the conductive gel, wound healing and nerve regeneration are promoted with the exosomeof the traditional Chinese medicine, and the problems in the current wound repair and nerve repair process can be effectively solved. Therefore, the composite dressing has a wide application value inthe treatment of trauma and nerve repair.

The invention relates to a new type of liver targeted drug carrier- glycyrrhetate modified chitosan/ carboxylated chitosan compound drug carrier nanometer particle as well as its preparing method. The preparing procedure includes the following steps: dissolving the glycyrrhetate into carboxylated chitosan of a certain density; adding certain amount of chitosan solution which contains drug into the carboxylated chitosan while stirring; nanometer particles form automatically because of the electrostatic interaction among different molecules. The invention has simple preparing procedures, mile operating conditions and it has no poisoning or side effects of the organic solvents. Since the glycyrrhizin has characteristic of targeting at the liver, the product in the invention has the function of active targeting which leads to high effect liver targeting capabilities. The invention is applicable to the entrapment of medicine that contains electrical group (such as doxorubicin hydrochloride), protein drugs and medicine that has certain water-solubility in neutral pH conditions.

The invention discloses application of a substituted benzene guanidine derivative serving as a polymyxins antibiotic potentiator. For the first time, the substituted benzene guanidine derivative is found to be capable of serving as the polymyxins antibiotic potentiator, especially serving as a synergist of a polymyxins antibiotic to inhibit sensitive strains and a drug resistance reversal agent of the polymyxins antibiotic. The invention further provides combined application of the substituted benzene guanidine derivative or a combination containing the same and the polymyxins antibiotic in preparation of compound drug preparations for people or animals to treat diseases caused by gram-negative bacterial infection. The invention further provides combined application of the substituted benzene guanidine derivative or a combination containing the same and the polymyxins antibiotic in preparation of forage-use growth-promoting feed additives for animal breeding in animal husbandry.

The invention discloses a drug composition containing amlodipine besylate and candesartan cilexetil and a drug box thereof, wherein, the weight ratio of the amlodipine besylate to the candesartan cilexetil is 1:1-6. The compound drug has a better synergistic effect in reducing blood pressure and extending blood vessels, and can be used for curing cardiovascular diseases such as hypertension and coronary heart disease.

The invention discloses a method for deoxidization by combining compound drugs and UV, which relates to a deoxidization method. The method solves problems of expensive equipment, complex operation and slow deoxidization speed in the conventional physical deoxidization technology, and also solves the problems of expensive catalysts, large dose, contained heavy metals and slow deoxidization speed in the chemical deoxidization technology. The method comprises the following step: adding deoxidization compound drugs into a reaction system, and irradiating with ultraviolet to finish the deoxidization. The method can efficiently and stably remove dissolved oxygen in air and water without expensive equipment and components, and has advantages of simple operation, safety, fast deoxidization speed, no need of expensive catalysts, no contained heavy metals, less dose, cost conservation, less effect on water quality and no special requirements on air impurities in the reaction system, and water quality indexes such as pH value in water, temperature, salinity, organics and the like. Therefore, the method can be widely applied to deoxidization in air and water.

The invention discloses an eye use compound drug combination containing lotepredenol etabonate and tobramycin. The combination contains less than 0.1 percent of tetra chloro metlbond. The preparation method of the drug combination is simple and is suitable for industrial production.

The invention discloses a beta- lactamase suppressing antibacterial compound drugs, which comprises ceftizoxime, or cefodizime and beta-lactam enzyme inhibitor by the active acid weight ratio of 1-10:10-1, which are in the forms of alkali metal salts or free acid and assisting solvents, the beta-lactam enzyme inhibitor can be Tazobactam, or clavulanic acid, or tapazole or their derivatives.

The invention discloses a compound drug for controlling citrus canker, comprising the following components in percentage by weight: 22.5%-30% of allicin, 36%-48% of streptomycin, 6% of wetting diffusant and the balance of kieselguhr filler. The 6% of wetting diffusant consists of 2% of sodium butyl naphthalene sulfonate (NEDALBA-75), 2% of sodium lignin sulfonate (M-9), 1% of lauryl alcohol polyoxyethylene ether (JFC) and 1% of carboxymethylcellulose (CMC). The compound drug for controlling the citrus canker can be used for controlling treetop citrus canker and fruit canker, is the low toxicity and residual free super active biogenic bactericide, has specially good effect on the canker and the control efficiency of more than 80 percent, is safe for fruit tress and is environmentally friendly; and the compound drug has the function of repelling pests spreading the citrus canker and can effectively reduce wounds and cut off propagation paths.

The invention discloses a pharmacokinetic-pharmacodynamic analytical method for effective components of compound drugs, the pharmacokinetic-pharmacodynamic combination model program of which comprises a pharmacodynamic parameter computation model and a pharmacokinetic parameter computation model. The analytical method comprises the following steps: the test data of a plurality of groups of drugs are read; a pharmacokinetic model is selected for model fitting and the computation of pharmacokinetic parameters; divided weight coefficients of each group are input for the computation of synthesized pharmacokinetic coefficients; a plurality of pharmacodynamic test data are read; drug concentration is computed according to the synthesized pharmacokinetic parameters obtained; the pharmacokinetic model is selected for the fitting of pharmacokinetic-pharmacodynamic parameters; the maximum pharmacodynamic parameter is computed and effect estimation values are output. The pharmacokinetic-pharmacodynamic analytical method for effective components of compound drugs can take the contribution relationship of varying effective components in the compound drugs to synthesized drug effects into consideration according to the effect-time curve area, meanwhile, a plurality of groups of data can be read for analysis and the synthesized pharmacokinetic-pharmacodynamic parameters of the compound drugs are computed to provide better guide to clinical medication.

The invention discloses a compound drug-carrying liposome as well as a preparation method and application thereof. The compound drug-carrying liposome comprises a long-circulating liposome and medicinal active ingredients coated by the long-circulating liposome, wherein the long-circulating liposome is a liposome of which the surface is modified by distearoyl phosphoethanolamine-methoxy polyethylene glycol 2000; the medicinal active ingredients refer to anthracycline antibiotics and resveratrol. The preparation method of the compound drug-carrying liposome comprises preparing a liposome source, the distearoyl phosphoethanolamine-methoxy polyethylene glycol 2000 and the medicinal active ingredients into the compound drug-carrying liposome, wherein the medicinal active ingredients refer to anthracycline antibiotics and resveratrol. The compound drug-carrying liposome disclosed by the invention has inhibitory activity on the development of drug-sensitive tumors, can effectively inhibit the development of chemotherapeutic drug-tolerant tumors and is small in side effect, thereby achieving a great clinical application value.

An N-phenylarylsulfonylamide compound of formula (I)

(R¹ is COOH etc.; R² is hydrogen, methyl, etc.; R³ and R⁴ are a combination of methyl and methyl, etc.; R⁵ is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E₂ receptor, especially an EP₁ subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.

The invention provides a compound shown in Formula I, an isomer, pharmaceutically-acceptable salt or solvate thereof, a preparation method thereof and application thereof in preparation of drugs for preventing and/or treating diseases caused by a Coxsackie virus. According to the invention, the compound keeps the activity of inhibiting the Coxsackie virus group B; and meanwhile, the pharmacokinetic parameters and safety of the compound drug are improved, thus indicating that the compound provided by the invention has favorable druggability and application prospects. The Formula I is shown in the specification.

The invention discloses a small molecule hydrogel-nanoparticle compound drug carrier and application thereof in skin/mucosa drug delivery system. The small molecule hydrogel-nanoparticle compound drugcarrier comprises drug-carrying nanoparticles and small molecule hydrogel, wherein the drug-carrying nanoparticles are dispersed in the small molecule hydrogel, and the surfaces of the nanoparticlesare modified with cell penetrating peptides. The small molecule hydrogel-nanoparticle compound drug carrier is used for skin/mucosa drug delivery, the skin/mucosa and lesion part penetrating performance of drugs can be evidently increased by modifying the surfaces of the nanoparticles with the cell penetrating peptides, and the problem that solution-dosage-form drug delivery is prone to drug lossis solved by the small molecule hydrogel.

The invention relates to a compound drug used for treating cervical syndrome. The effective components of the compound drug are prepared by following raw medicines: black snake, degelatined deerhorn, stir-baked squama manitis, caulis millettiae, centipede, paeonide alba, drynaria, curare (raw or prepared) or curare powder, libanus, myrrh, parasite scurrula, erythrinae, red ginseng, cibot rhizome and one or a plurality of epimedium, Chinese clematis root, incised notopterygium, angelica tuhov, lignum sappan, tuberculate speranskia herb, lycopodii, kudzuvine root, or thomson kudzu, atractylodes macrocephala, prepared rhizome of rehmannia, pyritum, dipsaci and scorpio. The preparation forms include oral preparation and external preparation. The invention composition can effectively treat cervical spondylosis, in particular to patients with the neck type and nerve root cervical spondylosis.

The invention discloses an application of a rhodiola rosea compound drug in preparing a drug for treating duodenal ulcer. The drug is prepared by the following active ingredients by in parts by weight: 4.2-7.2 parts of rhodiola rosea, 14-26 parts of poria cocos, 10.5-19.5 parts of dandelion, 10.5-19.5 parts of oriental wormwood, 10.5-19.5 parts of bighead atractylodes rhizome, 7-13 parts of patchouli, 7-13 parts of raw malts, and 3.5-6.5 parts of cardamon. The drug is precise and appropriate in compatibility and less in drug flavor, ensures the drug efficacy, reduces side effects, and can effectively treat the duodenal ulcer, and a new administration selection is provided for clinical administration.

The invention belongs to the technical field of medical apparatuses and instruments and relates to a compound drug coated balloon catheter and a preparation method thereof. The compound drug coated balloon catheter comprises a balloon and a drug coating which covers the surface of the balloon. The drug coating comprises an active drug and a carrier in a mass ratio of 0.2-20, the carrier comprisesa low-molecular-weight carrier and a high-molecular-weight carrier in a mass ratio of 0.5-10, and the drug loading capacity is 0.5-10microgram/mm<2>. The compound drug coated balloon catheter and thepreparation method thereof have advantages that fast drug transferring and reduction of loss in a delivery process are both realized, and integrality of the coating of the drug balloon is guaranteed;after the drug is transferred to the vascular tissue, part of the drug is temporarily fixed in the carrier and cannot be released, and along with degradation and/or dissolution of the high-molecular-weight carrier, the drug is released step by step, so that retention time of the drug in the tissue is prolonged, long-time inhibition of tissue hyperplasia can be realized, and the intravascular stenosis rate is decreased.

The invention relates to a preparation method of a drug carrying microsphere, particularly to a preparation method of chitosan and montmorillonite compound drug carrying microsphere. The preparation method comprises the following steps: firstly, weighing quantitative chitosan, dissolving the chitosan into 50-100 ml of acetum to prepare a 1-2% (w/v) chitosan acetum, wherein the degree of deacetylation of the chitosan is 80.0-95.0%, the volume fraction of the acetum is 2-3%; weighing and dispersing quantitative officinal calcium-based montmorillonite into 100-200 ml of deionized water, setting relevant parameters in a microwave reactor, dropwise adding 0.5-0.8 g/l sodium pyrophosphate into a prepared chitosan/ montmorillonite mixed solution to obtain a chitosan/montmorillonite compound microsphere solution, wherein the content of the montmorillonite is greater than 99%; finally freeze-drying the chitosan/montmorillonite compound microsphere solution. According to the invention, chitosan/montmorillonite compound microsphere is used as a carrier for preparing a lung targeted drug, environmentally friendly, non-toxic, simple in preparation processes and low in preparation cost, and has the characteristics of high mechanical and thermal stabilities, excellent dispersity and structure, and ideal medicine carrying.

Embodiments of the invention provide a method for green extraction and determination of a variety of compounds in the Chinese herbal compound drug Naoxintong. The method comprises the following steps: (1) acquiring liquid extract of a Naoxintong sample by using a matrix solid-phase dispersion extraction process, wherein the mass of the Naoxintong sample is 10-50 mg, an adsorbent is magnesium silicate, a mass ratio of the Naoxintong sample and the adsorbent is (2: 1) to (1: 5), an eluent is methanol with a concentration of 60% to 100 % and contains 0-0.2% by volume of formic acid, the ratio of the mass of the Naoxintong sample to an elution volume is 25-42 mg/mL, and grinding time of the Naoxintong sample and the adsorbent is 0-8 minutes; and (2) analyzing the liquid extract of the Naoxintong sample by using ultra-high performance liquid chromatography so as to determine the contents of the compounds in the Chinese herbal compound drug Naoxintong. The determination method provided by the invention can provide a theoretical basis for the validation studies of traditional Chinese medicines and provide technical support for the quality control of Naoxintong.

The invention provides a compound with antitumor activity, and a preparation method and application thereof, and relates to the technical field of chemical compounding drugs. The compound is of a structure shown as a formula (I) or (II). The stimuli-responsive self-assembly unimolecular compound with the antitumor activity is prepared through condensation reaction between hepatic-targeting water-soluble lactose and a platinum (IV) compound. The compound has the advantages that hepatic-targeting water-soluble lactose molecules are introduced, water-solubility of the platinum (IV) compound is improved, and hydrophilic-lyophobic balance is achieved, so that the self-assembly unimolecular platinum (IV) compound is formed, cytotoxicity of the platinum (IV) compound is reduced, a compounded tetravalence platinum prodrug has amphipathy, and accumulation degree of hepatoma cells can be increased; due to platinum, activation and release of the platinum compound are benefited under the conditions of external photostimulation or intracellular reduction, and accordingly, high antitumor activity is achieved.

The invention relates to the field of natural drugs, and discloses medical application of natural product 6-shogaol in enhancing the chemosensitivity of pancreatic cancer on gemcitabine and a compound drug composite of the natural product 6-shogaol. According to the invention, low-dose gemcitabine can generate biological effect under high dose through the combined administration of the 6-shogaol and the gemcitabine, so that the clinical usage amount of the gemcitabine can be greatly reduced, the toxic side effect can be reduced, the clinical treatment safety index can be enhanced, and good clinical application development prospect is achieved.